ACR President Carol A. Langford, MD, MPH, highlights the importance of research in the field and where to find resources and initiatives within the ACR to support, fund, inspire, and enhance innovation. For more on this important topic, see Dr. Langford’s column in the January issue of The Rheumatologist.

RA: How High Is the Toll?
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.

President’s Corner: ACR Initiatives Support Research at Every Level
For me, few ACR events bring home our connection as a rheumatology community more than our annual meeting, ACR Convergence. In addition to its many important opportunities for networking and education, one aspect of the meeting that always inspires me is the research. Research represents one of the three priorities of my presidential term because…

Youthful Exuberance: The Year in Review for Pediatric Rheumatology
WASHINGTON, D.C.—It is no small task to summarize an entire year’s worth of research accomplishments in any field of medicine, let alone one as complex as rheumatology. At ACR Convergence 2024, the Pediatric Year in Review not only provided a thoughtful summary, but also grouped advances along several different themes. Immune Health & More Jessica…
Prevalence of Fibromyalgia & Widespread Pain in Psoriatic Arthritis: Association with Disease Severity Assessment in a Large U.S. Registry
According to a new study, fibromyalgia prevalence is elevated in PsA and is associated with elevated disease measures, confounding reliable disease assessment for treat-to-target goals.
What Clinical Factors Affect Length of Transition to Psoriatic Arthritis in Patients with Psoriasis?
Objective We aimed to identify clinical and demographic features associated with the interval between the appearance of psoriasis and the onset of psoriatic arthritis (PsA). Methods We identified patients with psoriasis and PsA diagnoses from our tertiary care psoriatic disease biorepository: a longitudinal, real-world database including clinical information and patient-reported outcomes. We used a multivariable,…

Top Research in Psoriatic Arthritis Presented at ACR Convergence 2024
Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…

Systemic Lupus Erythematosus: A Complex, Multi-Challenging Disease
Reviewing the research presented at ACR Convergence 2024.

AC&R Study Summary: Standardizing Treatment for Moderately Severe JDM
Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…
Cardiovascular & Cancer Risk Factors with JAK Inhibitors
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 127
- Next Page »